Common use of Novartis: Special Consequences of Certain Terminations Clause in Contracts

Novartis: Special Consequences of Certain Terminations. If Novartis terminates this Agreement under Section 11.2.2(a), Section 11.2.3(a) or Section 11.2.5, all of the provisions of Section 11.3.1 will apply, except that Novartis, its Affiliates, and Sublicensees will have the right to sell any remaining inventory of Product and Novartis will pay Akcea royalties in accordance with Section 7.8 on the Net Sales of such inventory of such Products to the extent not already paid (unless Akcea elects to have Novartis continue to sell the applicable Terminated Product as part of the Transition Services under Section 11.3.4 (in which case Akcea will own all revenue derived from the Product after the termination date)).

Appears in 4 contracts

Samples: Strategic Collaboration, Option and License Agreement (Ionis Pharmaceuticals Inc), Option and License Agreement (Akcea Therapeutics, Inc.), Option and License Agreement (Akcea Therapeutics, Inc.)

AutoNDA by SimpleDocs
Time is Money Join Law Insider Premium to draft better contracts faster.